These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 15387111)

  • 1. Use of high-dose human intravenous immunoglobulin therapy in sensitized patients awaiting transplantation: the Cedars-Sinai experience.
    Jordan SC; Vo AA; Nast CC; Tyan D
    Clin Transpl; 2003; ():193-8. PubMed ID: 15387111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience.
    Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
    Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperimmunized patients awaiting cadaveric kidney graft: is there a quick desensitization possible?
    Faenza A; Fuga G; Bertelli R; Scolari MP; Buscaroli A; Stefoni S
    Transplant Proc; 2008; 40(6):1833-8. PubMed ID: 18675064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desensitizing the broadly human leukocyte antigen-sensitized patient awaiting deceased donor kidney transplantation.
    Jordan SC; Reinsmoen N; Lai CH; Cao K; Kahwaji J; Peng A; Villicana R; Vo A
    Transplant Proc; 2012 Jan; 44(1):60-1. PubMed ID: 22310579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients.
    Jordan SC; Vo A; Bunnapradist S; Toyoda M; Peng A; Puliyanda D; Kamil E; Tyan D
    Transplantation; 2003 Aug; 76(4):631-6. PubMed ID: 12973100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience.
    Thielke JJ; West-Thielke PM; Herren HL; Bareato U; Ommert T; Vidanovic V; Campbell-Lee SA; Tzvetanov IG; Sankary HN; Kaplan B; Benedetti E; Oberholzer J
    Transplantation; 2009 Jan; 87(2):268-73. PubMed ID: 19155983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Desensitization protocols in immunized living donor kidney transplant recipients].
    Nocera A
    G Ital Nefrol; 2009; 26(4):499-515. PubMed ID: 19644839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
    Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
    Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kidney transplant in highly sensitized patients after desensitization with plasmapheresis and low-dose intravenous immunoglobulin.
    Yuan XP; Wang CX; Gao W; Fu Q; He XS
    Exp Clin Transplant; 2010 Jun; 8(2):130-5. PubMed ID: 20565369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial.
    Jordan SC; Tyan D; Stablein D; McIntosh M; Rose S; Vo A; Toyoda M; Davis C; Shapiro R; Adey D; Milliner D; Graff R; Steiner R; Ciancio G; Sahney S; Light J
    J Am Soc Nephrol; 2004 Dec; 15(12):3256-62. PubMed ID: 15579530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous immunoglobulin, HLA allele typing and HLAMatchmaker facilitate successful transplantation in highly sensitized pediatric renal allograft recipients.
    Valentini RP; Nehlsen-Cannarella SL; Gruber SA; Mattoo TK; West MS; Lang C; Imam AA
    Pediatr Transplant; 2007 Feb; 11(1):77-81. PubMed ID: 17239127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post-transplant therapy with high-dose intravenous gammaglobulin: Applications to treatment of antibody-mediated rejection.
    Jordan SC; Vo AA; Toyoda M; Tyan D; Nast CC
    Pediatr Transplant; 2005 Apr; 9(2):155-61. PubMed ID: 15787786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Desensitization strategies enabling successful renal transplantation in highly sensitized patients.
    Beimler JH; Susal C; Zeier M
    Clin Transplant; 2006; 20 Suppl 17():7-12. PubMed ID: 17100695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation.
    Vo AA; Peng A; Toyoda M; Kahwaji J; Cao K; Lai CH; Reinsmoen NL; Villicana R; Jordan SC
    Transplantation; 2010 May; 89(9):1095-102. PubMed ID: 20110854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donor-specific antibodies against HLA, MICA, and GSTT1 in patients with allograft rejection and C4d deposition in renal biopsies.
    Alvarez-Márquez A; Aguilera I; Gentil MA; Caro JL; Bernal G; Fernández Alonso J; Acevedo MJ; Cabello V; Wichmann I; Gonzalez-Escribano MF; Núñez-Roldán A
    Transplantation; 2009 Jan; 87(1):94-9. PubMed ID: 19136897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kidney transplantation in the United States.
    Cecka JM
    Clin Transpl; 2008; ():1-18. PubMed ID: 19711510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasmapheresis and intravenous immunoglobulin in early antibody-mediated rejection of the renal allograft: a single-center experience.
    Slatinska J; Honsova E; Burgelova M; Slavcev A; Viklicky O
    Ther Apher Dial; 2009 Apr; 13(2):108-12. PubMed ID: 19379149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using donor exchange paradigms with desensitization to enhance transplant rates among highly sensitized patients.
    Montgomery RA; Lonze BE; Jackson AM
    Curr Opin Organ Transplant; 2011 Aug; 16(4):439-43. PubMed ID: 21666478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients.
    Billing H; Rieger S; Ovens J; Süsal C; Melk A; Waldherr R; Opelz G; Tönshoff B
    Transplantation; 2008 Nov; 86(9):1214-21. PubMed ID: 19005402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection.
    Fehr T; Rüsi B; Fischer A; Hopfer H; Wüthrich RP; Gaspert A
    Transplantation; 2009 Jun; 87(12):1837-41. PubMed ID: 19543061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.